Eli Lilly and Company (NYSE:LLY – Get Rating) major shareholder Lilly Endowment Inc sold 118,856 shares of the company’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $302.73, for a total transaction of $35,981,276.88. Following the completion of the sale, the insider now directly owns 105,353,810 shares in the company, valued at approximately $31,893,758,901.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

• On Wednesday, May 18th, Lilly Endowment Inc sold 700 shares of Eli Lilly and stock. The shares were sold at an average price of $302.00, for a total transaction of $211,400.00.
• On Monday, May 16th, Lilly Endowment Inc sold 80,761 shares of Eli Lilly and stock. The shares were sold at an average price of $302.53, for a total transaction of $24,432,625.33.
• On Friday, April 8th, Lilly Endowment Inc sold 139,045 shares of Eli Lilly and stock. The shares were sold at an average price of $310.79, for a total transaction of $43,213,795.55.
• On Wednesday, April 6th, Lilly Endowment Inc sold 51,851 shares of Eli Lilly and stock. The shares were sold at an average price of $300.92, for a total transaction of $15,603,002.92.
• On Monday, April 4th, Lilly Endowment Inc sold 39,393 shares of Eli Lilly and stock. The shares were sold at an average price of $293.15, for a total transaction of $11,548,057.95.
• On Friday, April 1st, Lilly Endowment Inc sold 165,376 shares of Eli Lilly and stock. The shares were sold at an average price of $292.38, for a total transaction of $48,352,634.88.
• On Wednesday, March 30th, Lilly Endowment Inc sold 2,500 shares of Eli Lilly and stock. The shares were sold at an average price of $292.03, for a total transaction of $730,075.00.
• On Monday, March 28th, Lilly Endowment Inc sold 7,538 shares of Eli Lilly and stock. The shares were sold at an average price of $292.15, for a total transaction of $2,202,226.70.
• On Monday, March 21st, Lilly Endowment Inc sold 35,245 shares of Eli Lilly and stock. The stock was sold at an average price of $292.43, for a total transaction of $10,306,695.35.
• On Thursday, March 17th, Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock. The stock was sold at an average price of $283.80, for a total transaction of $62,436,000.00.

NYSE:LLY traded up $2.83 during trading hours on Tuesday, hitting $305.43. The stock had a trading volume of 64,306 shares, compared to its average volume of 2,929,607. Eli Lilly and Company has a one year low of $195.50 and a one year high of $314.00. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The company has a market cap of $290.21 billion, a price-to-earnings ratio of 45.01, a P/E/G ratio of 2.27 and a beta of 0.40. The business’s 50 day moving average is $292.90 and its 200-day moving average is $268.14.

Eli Lilly and (NYSE:LLY – Get Rating) last issued its earnings results on Thursday, April 28th. The company reported $2.62 EPS for the quarter, beating the consensus estimate of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The firm had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. During the same quarter in the prior year, the firm earned $1.87 earnings per share. The business’s quarterly revenue was up 14.8% on a year-over-year basis. On average, sell-side analysts anticipate that Eli Lilly and Company will post 8.25 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Monday, May 16th will be given a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.28%. The ex-dividend date of this dividend is Friday, May 13th. Eli Lilly and’s dividend payout ratio is 58.07%.

Several hedge funds have recently modified their holdings of LLY. Cordant Inc. bought a new stake in shares of Eli Lilly and during the first quarter worth $25,000. Wagner Wealth Management LLC boosted its holdings in Eli Lilly and by 59.4% during the third quarter. Wagner Wealth Management LLC now owns 110 shares of the company’s stock worth $28,000 after purchasing an additional 41 shares during the last quarter. AllSquare Wealth Management LLC acquired a new position in Eli Lilly and during the fourth quarter worth $28,000. HWG Holdings LP acquired a new position in Eli Lilly and during the fourth quarter worth $28,000. Finally, Icapital Wealth LLC acquired a new position in Eli Lilly and during the first quarter worth $28,000. 82.75% of the stock is owned by institutional investors.

A number of equities analysts have recently issued reports on LLY shares. Bank of America upped their target price on shares of Eli Lilly and from $300.00 to $315.00 in a research report on Thursday, March 17th. Mizuho upped their target price on shares of Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Daiwa Capital Markets started coverage on shares of Eli Lilly and in a research report on Thursday, March 10th. They set an “outperform” rating and a $286.00 target price on the stock. Morgan Stanley upped their target price on shares of Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. Finally, SVB Leerink began coverage on shares of Eli Lilly and in a report on Monday. They issued an “outperform” rating and a $341.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and presently has a consensus rating of “Buy” and a consensus price target of $304.58.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Receive News & Ratings for Eli Lilly and Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and and related companies with MarketBeat.com’s FREE daily email newsletter.